

ATTORNEY DOCKET NO.: 056291-5004

Application No.: 09/756,291

Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

Claims 1-23 (cancelled)

11 Claim ~~24~~ (previously amended): A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle, whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml^{-1} is attained for at least 2 weeks after injection.

2 Claim ~~25~~ (previously added): The method as claimed in claim ~~24~~ wherein the benign or malignant disease is breast cancer.

3 Claim ~~26~~ (previously added): The method as claimed in claim ~~24~~ wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks after injection.

4 Claim ~~27~~ (previously added): The method as claimed in claim ~~24~~ wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks after injection.

5 Claim ~~28~~ (previously amended): A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle whereby the formulation comprises at least 45mgml^{-1} of fulvestrant.

ATTORNEY DOCKET NO.: 056291-5004
Application No.: 09/756,291
Page 3

Claims 29 - 44 (cancelled).

^{1 5}
6 Claim ~~45~~ (previously added): The method as claimed in claim ~~24~~ or ~~28~~ wherein the total volume of the formulation administered to said human is 6ml or less, and the concentration of fulvestrant in said formulation is at least 45mgml⁻¹.

^{1 5}
7 Claim ~~46~~ (previously added): The method as claimed in claim ~~24~~ or ~~28~~ wherein the total volume of the formulation administered to said human is 6ml or less, and the total amount of fulvestrant in said volume of formulation is 250mg or more.

⁷
8 Claim ~~47~~ (previously amended): The method as claimed in claim ~~46~~ wherein the total volume of the formulation is from 5 to 5.25ml, and the total amount of fulvestrant in said volume of formulation is 250mg.

Claim 48 - 50 (cancelled).

⁵
9 Claim ~~51~~ (new): The method as claimed in claim ~~28~~ wherein the benign or malignant disease is breast cancer.